Neurobiology of panic disorder

Journal of Psychosomatic Research

Volumn 44, Issue 1, 1998, Pages 163-180

  Bourin, Michel ^a   Baker, G B ^c   Bradwejn, J ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c NONE

Author keywords

5 Hydroxytryptamine; Cholecystokinin; GABA; Norepinephrine; Panic disorder; Provocative agents

Indexed keywords

CAFFEINE; CARBON DIOXIDE; CHOLECYSTOKININ; LACTATE SODIUM; SEROTONIN AGONIST; YOHIMBINE;

HUMAN; NEUROBIOLOGY; PANIC; REVIEW;

EID: 0031963664     PISSN: 00223999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3999(97)00203-1     Document Type: Article

References (153)

1. 1. Bourin M, Malinge M, Guitton B. Provocative agents in panic disorder. Thérapie 1995;50:301-306.
2. 2. Pitts FM, McClure JN, Lactate metabolism in anxiety neurosis. N Engl J Med 1967;277:1329-1336.
3. 3. Nutt D, Lawson C. Panic attacks: A neurochemical overview of models and mechanisms. Br. J. Psychiatry 1992;160:165-178.
4. 4. Coupland NJ, Nutt DJ, Neurobiology of anxiety and panic. In: Bradwejn J, Vasar E, eds. Cholecystokinin and anxiety: from neuron to behaviour. New York: Springer 1995:1-32.
5. 5. Cowley DS, Dager SR, Dunner DL. Lactate induced panic in primary affective disorder. Am J Psychiatry 1986;143:646-648.
6. 6. McGrath PJ, Stewart JW, Liebowitz MR. Lactate provocation of panic attacks in depressed outpatients. Psychiatry Res 1988;25:41-47.
7. 7. Liebowitz MR, Fyer AJ, Gorman JM, Dillon D, Davies S, Stein JM, Cohen BS, Klein DF. Specificity of lactate infusions in social phobia versus panic disorders. Am J Psychiatry 1985;142:947-950.
8. 8. Yeragani VK, Pohl R, Balon R, Weinberg P, Berchou R, Rainey J. Preinfusion anxiety predicts lactate-induced panic attacks in normal controls. Psychosom Med 1987;49:383-389.
9. 9. Carr DB, Sheehan DV, Surman OS, Coleman JH, Greenblatt DJ, Heninger GR, Jones KJ, Levine PH, Watkins WD. Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am J Psychiatry 1986;143:483-494.
10. 10. Pohl R, Ettedgui E, Bridges M. Plasma MHPG levels in lactate and isoproterenol anxiety states. Biol Psychiatry 1987;22:1127-1136.
11. 11. Gaffney FA, Fenton BJ, Lane LD, Lake CR. Hemodynamic, ventilatory, an biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks. Arch Gen Psychiatry 1988;45:53-60.
12. 12. Nutt D, Lawton C. Panic attacks: a neurochemical overview of models and mechanisms. Br J Psychiatry 1992;160:165-178.
13. 13. Gorman JM, Battista D, Goetz RR, et al. A comparison of sodium bicarbonate and sodium lactate infusion of panic attacks. Arch Gen Psychiatry 1989;46:145-150.
14. 14. Gorman JM, Goetz RR, Dillon D. Sodium D-lactate infusion in panic disorder patients. Neuropsychopharmacology 1990;3:181-189.
15. 15. Dager SR, Marro KI, Richards TL, Metzger GD. Preliminary application of magnetic resonance spectroscopy to investigate lactate-induced panic. Am J Psychiatry 1994;151:57-63.
16. 16. Dager SR, Strauss WL, Marro KI, Richards TL, Metzger GD, Artru AA. Proton magnetic resonance spectroscopy investigation of hyperventilation in subjects with panic disorder and comparison subjects. Am J Psychiatry 1995;152:666-672.
17. 2 vulnerability in panic disorder. Am J Psychiatry 1987;144:1080-1082.
18. 2 challenge of patients with panic disorder. Am J Psychiatry 1987;144:1080-1082.
19. 2 with hyperventilation in patients with panic disorder. Am J Psychiatry 1994;151:547-553.
20. 2 challenges. Am J Psychiatry 1995;152:85-89.
21. 2 challenge in panic and mood disorders. J Affect Disord 1995;33:189-194.
22. 22. Perna G, Cocchi S, Bertani A, Arancio C, Bellodi L. Pharmacologic effect of toloxatone on reactivity to the 35% carbon dioxide challenge: a single-blind, random, placebo-controlled study. J Clin Psychopharmacol 1994;14:414-418.
23. 23. Sanderson WC, Rapee RM, Barlow DH. The influence of an illusion of control on panic attacks induced via inhalation of 5.5% carbon dioxide enriched air. Arch Gen Psychiatry 1989;46:157-162.
24. 24. Klein DF, Gorman JM. A model of panic and agoraphobic development. Acta Psychiatrica Scand 1987;335:87-95.
25. 25. Charney DS, Woods SW, Krystal JH. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder. Acta Psychiatrica Scand 1992; 86:273-282.
26. 26. Albus M, Zahn TP, Breier A. Anxiogenic properties of yohimbine. Behavioral, physiological and biochemical measures. Eur Arch Psychiatry Clin Neurosci 1992;241:337-344.
27. 27. Yerangi VK, Berger R, Pohl R. Effects of yohimbine on heart rate variability in panic disorder patients and normal controls: a study of power spectral analysis of heart rate. J Cardiovasc Pharmacol 1992;20:609-618.
28. 28. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987;144:1030-1036.
29. 29. Goddard AW, Woods SW, Sholomskas DE. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 1993;48:119-133.
30. 30. Uhde, TW. Caffeine: practical facts for the psychiatrist. In: Roy-Byrne PP, ed. Anxiety: new research findings for the clinician. Washington, DC: American Psychiatric Press 1988:73-98.
31. 31. Boulenger JP, Uhde TW. Caffeine consumption and anxiety: preliminary results of a survey comparing patients with anxiety disorders and normal controls. Psychopharmacol Bull 1982;18:53-57.
32. 32. Uhde TW, Boulanger JP, Vittone B, Jimerson DC, Post PM. Caffeine: relationship to human anxiety plasma MHPG and cortisol. Psychopharmacol Bull 1984;20:426-430.
33. 33. Charney DS, Heninger GR, Jallon PI. Increased anxiogenic effects of caffeine in panic disorder. Arch Gen Psychiatry 1985;42:233-243.
34. 34. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991;30:1139-1166.
35. 35. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989;28:295-306.
36. 36. Charney D, Woods S, Goodman W. Serotonin function in anxiety: II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology 1987;92:14-24.
37. 37. Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazìne given intravenously or orally to healthy volunteers. Psychopharmacology 1989;98:275-282.
38. 38. Den Boer JA, Westenberg HGM. Behavioral neuroendocrine and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res 1990;31:267-278.
39. 39. Johnson MR, Lydiard RB, Ballenger JC. Panic disorder: pathophysiology and drug treatment. Drugs 1995;49:328-344.
40. 40. Crawley JN. Comparative distribution of cholecystokinin and other neuropeptides. Ann NY Acad Sci 1985;448:1-8.
41. 41. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994;15:731-755.
42. 42. Rehfeld JF, Neilsen FC. Molecular forms and regional distribution of cholecystokinin in the central nervous system. In: Bradwejn J, Vasar E, eds. Cholecystokinin and anxiety: from neuron to behavior. New York: Springer 1995:33-56.
43. 43. Wank SA, Harkins R, Jensen RT, Shapira H, De Weerth A, Slattery T. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci USA 1992;89:3125-3129.
44. 44. Woodruff GN, Hughes J. Cholecystokinin antagonists. Ann Rev Pharmacol Toxicol 1991;31: 469-501.
45. 45. Wettstein JG, Buéno L, Hunien JL. CCK antagonists: pharmacology and therapeutic interest. Pharmacol Ther 1994;62:267-282.
46. 46. Lena I, Roques BP, Durieux C. Dual modulation of dopamine release from anterìor nucleus accumbens through cholecystokinin-B receptor subsites. J Neurochem 1997;68:162-168.
47. 47. Bradwejn J, de Montigny C. Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. Nature 1984;312:363-364.
48. 48. Bradwejn J, Koszycki D, Meterissian G. Cholecystokinin-tetrapeptide induced panic attacks in patients with panic disorder. Can J Psychiatry 1990,35:83-85.
49. 49. Bradwejn J, Koszycki D, Payeur R. Cholecystokinin-tetrapeptide: a provocative agent for research in panic disorders? In: Briley M, File S, eds. New concepts in anxiety. London: MacMillan 1991:313-319.
50. 50. Guttmacher LB, Murphy DL, Insel TR. Pharmacologic models of anxiety. Compreh Psychiatry 1983;24:312-326.
51. 51. Gorman JM, Fyer MR, Liebowitz MR, Klein DF. Pharmacologic provocation of panic attacks. In: Meltzer HY ed. Psychopharmacology: a third generation of progress. New York: Raven Press 1987:980-983.
52. 52. Bradwejn J, Koszycki D, Payeur R, Bourin M. CCK-4 and panic disorder. In: Montgomery SA, ed. Psychopharmacology of panic. Oxford: Oxford University Press 1993:110-117.
53. 53. Bradwejn J, Koszycki D, Bourin M. Dose ranging study of the effect of CCK-4 in healthy volunteers. J Psychiatry Neurosci 1991;16:260-264.
54. 54. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokin tetrapeptide in panic disorder: clinical and behavioural findings. Arch Gen Psychiatry 1991;48:603-607.
55. 55. van Megen HJGM, Westenberg HGM, den Boer JA, Slaap B, Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacol 1997;129:357-364.
56. 2 induced panic attacks with cholecystokinin-induced panic attacks in panic disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 1991;15:237-239.
57. 57. Koszycki D, Bradwejn J, Bourin M. Comparison of the effects of cholecystokinin and carbon dioxide in healthy volunteers. Eur Neuropsycholpharmacol 1991;1:137-141.
58. 58. Bourin M, Malinge M, Vasar E, Bradwejn J. Two faces of cholecystokinin: anxiety and schizophrenia. Fundam Clin Pharmacol 1996;10:116-126.
59. 59. Bradwejn J, Koszycki D, Couëtoux du Tertre A, Paradis M, Bourin M. Flumazenil does not antagonise CCK-4 induced panic in healthy volunteers. Psychopharmacology 1994;114:257-261.
60. 60. Bradwejn N, Koszycki D, Couëtoux du Tertre A, van Megen H, den Boer J, Westenberg H, Annable L. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994;51:486-493.
61. 61. Bradwejn J, Koszycki D. Imipramine antagonizes the panicogenic effects of CCK-4 in panic disorder patients. Am J Psychiatry 1994;1511:261-263.
62. 62. Lines C, Challenor J, Traub M. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br J Clin Pharmacol 1995;39:235-242.
63. 63. Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, Shrivastava R, Matsura-Wolfe D, Lines C, Reines SA. A placebo-controlled trial of L-365,260, a CCK-B antagonist, in panic disorder. Biol Psychiatry 1995;37;462-466.
64. 64. Cutler NR, Sramek JJ, Kramer MS, Reines SA. Pilot study of a CCK-B antagonist in panic disorder. NCDEU 34th Annual Meeting, Marco Island, FL 1994.
65. 65. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 1995;38:742-746.
66. 66. van Megen, HJGM, Westenberg HGM, den Boer JA, Slaap B, van Es-Radhakishun F, Pande AC. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology 1997;129:243-248.
67. 67. Cowley DS, Bammert Adams J, Pyke RE, Cook J. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic. Biol Psychiatry 1996;40:550-552.
68. B receptor ligands in a validated simulation of panic anxiety in rats. Eur Neuropsychopharmacol 1996;6:291-298.
69. 69. Ervin F, Palmour R, Bradwejn J. A new primate model for panic disorder. New research program and abstracts: 144th meeting of the American Psychiatric Association, New-Orleans, LA May 14, NR 216:100, 1991.
70. 70. Palmour R, Ervin F, Bradwejn J. Cholecystokinin and anxiety: a non-human primate model. Proceedings of the 19th annual meeting of the Canadian College of Neuropsychopharmacology Toronto, ON, Canada, 1996.
71. 71. Bourin M, Bradwejn J, Vasar E, Palmour R. CCK provocation as a research tool in panic disorder. Eur Neuropsychopharmacol 1993;3:253-256.
72. 3 receptors, antagonizes the anti-exploratroy effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. Psychopharmacology 1993;110:213-218.
73. 73. Singh L, Lewis AS, Field MJ, Hugues J, Woodruff GN. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 1991;88:1130-1133.
74. 74. Lydiard RB. Neuropeptides and anxiety: focus on cholecystokinin. Clin Chem 1994;40:315-318.
75. 75. Branchereau P, Bohme GA, Champagnat J, Morin-Surin MP, Durieux C, Blanchard JC, Roques BP, Denavit-Saubie M. Cholecystokinin A and cholecystokinin B receptors in neurons of the brainstem solitary complex of the rat: pharmacological identification. J Pharmacol Exp Ther 1992;260:1433-1440.
76. 76. Mannistö PT, Lang A, Harro J, Peuranen E, Bradwejn J, Vasar E. Opposite effects mediated by CCK-A and CCK-B receptors in behavioural and hormonal studies in rats. Naunyn-Schmiedeberg's Arch Pharmacol 1994;349:478-484.
77. 77. van Megen HJGM, Westenberg HGM, den Boer JA, Kahn RS. Cholecystokinin in anxiety. Eur Neuropsychopharmacol 1996;6:263-280.
78. 78. Bradwejn J, Vasar E. Cholecystokinin and anxiety: from neuron to behaviour. New York: Springer 1995.
79. 79. Redmond DE Jr, Huang YH. Current concepts II: New evidence for a locus coeruleus norepinephrine connection with anxiety. Life Sci 1979;25:2149-2162.
80. 80. Ko GN, Elsworth JD, Roth RH, Rifkin BG, Leigh H, Redmond DE. Panic-induced elevation of plasma MHPG levels in phobic-anxious patients: effects of clonidine and imipramine. Arch Gen Psychiatry 1983;49:425-430.
81. 81. Uhde TW, Stein MB, Vittone BJ. Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry 1989;46:170-177.
82. 82. Roth M. The panic-agoraphobic syndrome: a paradigm of the anxiety group of disorders and its implications for psychiatric practice and theory. Am J Psychiatry 1996;153:111-124.
83. 83. Charney DS, Heninger GR, Redmond DE. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci 1983;33:19-29.
84. 84. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987;144:1030-1036.
85. 85. Cameron OG, Lee MA, Curton GC, McCann DS. Psychobiologic changes during "spontaneous" panic [abstract]. Psychosom Med 1985;47:308.
86. 86. Woods SW, Charney DS, McPherson CA, Gradman AH, Heninger GR. Situational panic attacks: behavioral, physiologic, and biochemical characterization. Arch Gen Psychiatry 1987;33:365-375.
87. 87. Abelson J, Glitz D, Cameron O. Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder. Biol Psychiatry 1992;32:18-25.
88. 88. Uhde T, Stein M, Vittone B. Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry 1989:46:170-177.
89. 89. Brambilla F, Bellodi L, Arancio C, Nobile P, Perna G. α-Adrenergic receptor sensitivity in panic disorder:II. Cortisol response to clonidine stimulation in panic disorder. Psychoneuroendocrinology 1995;20:11-19.
90. 90. Brambilla F, Perna G, Garberi A, Nobile P, Bellodi L. α-Adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidtne stimulation in panic disorder. Psychoneuroendocrinology 1995;20:1-9.
91. 91. Uhde TW, Tancer ME, Rubinow DR, Roscow DB, Boulenger JP, Vittone B, Gurguis G, Geraci M. Black B, Post RM. Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmacology 1992; 6:101-118.
92. 4 in patients with panic disorder. Eur Neuropsychopharmacol 1996;6:187-194.
93. 4 administration. Proceedings of the 19th annual meeting of the Canadian College of Neuropsychopharmacology, Toronto, ON Canada, 1996.
94. 4? Proceedings of the 19th annual meeting of the Can College of Neuropsychopharmacology, Toronto, ON, Canada, 1996.
95. 95. Nevo I, Becker C, Hamon M, Benoliel JJ. Stress-and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat: prevention by diazepam but not ondansetron. J Neurochem 1996;66:2041-2049.
96. 96. Sheehan BA, Raj RR, Knapp EL. Serotonin in panic disorder and social phobia. Int Clin Psychopharmacol 1993;8:63-77.
97. 97. Eriksson E. Brain neurotransmission in panic disorder. Acta Psychiatrica Scand 1993;335 (suppl):31-37.
98. 98. Iversen SD. 5-HT and anxiety, Neuropharmacology 1984;23:1353-1360.
99. 99. Aston-Jones G, Rajkowski J, Kubiak P. Locus ceruleus neurons in monkey are selectively activated by attended cues in a vigilant task. J Neurosci 1994;14:4467-4480.
100. 100. Goddard AW, Sholomskas DE, Walton KE, Augeri FM, Charney DS, Heninger GR, Goodman WK, Price LH. Effects of tryptophan depletion in panic disorder. Biol Psychiatry 1994;36:775-777.
101. 101. López-Rubalcava C, Saldìvar A, Fernández-Guasti A. Interaction of GABA and serotonin in the anxiolytic action of diazepam and serotonergic anxiolytics. Pharmacol Biochem Behav 1991;43: 433-440.
102. A receptors. Eur J Pharmacol 1994;268:237-246.
103. 103. Morales M, Battenberg E, deLecea L, Bloom FE. The type 3 serotonin receptor is expressed in a subpopulation of GABAergic neurons in the rat neocortex and hippocampus. Brain Res 1996; 731:199-202.
104. 3 receptor antagonists. Pharmacol Toxicol 1992;760:157-162.
105. 105. Paudice P, Raiteri M. Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens. Br J Pharmacol 1991;103:1790-1794.
106. 106. Raiteri M, Paudice P, Vallebuona F. Release of cholecystokinin in the central nervous system. Neurochem Int 1993;22:519-527.
107. 107. Rex A, Fink H, Marsden CA. Effects of BOC-CCK-4 and L-365,260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology 1994;33:559-565.
108. 108. Johnson MR. Lydiard RB, Ballenger JC. MAOIs in panic disorder and agoraphobia. In: Kennedy SH, ed. Clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: APA 1994:205-224.
109. 109. Boyer W. Serotonin uptake inhibitors are superior to imipramine in alleviating panic attacks. In: Darcourt G. Mendlewicz J, Racagni G, Brunello N, eds. Current therapeutic approaches in panic and other anxiety disorders, vol 8. Basel: Karger 1994:55-60.
110. 110. van Vliet IM, den Boer JA, Westenberg HGM, Slaap BR. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol 1996; 16:299-306.
111. 111. Westenberg HGM. Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? J Affect Disord 1996;40:85-93.
112. 112. Rimón R. Lepola U, Jolkkonen J, Halonen T, Riekkinen P. Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder. Biol Psychiatry 1995;38:737-741.
113. 113. Goddard AW, Narayan M, Woods SW, Germine M, Kramer GL, Davis LL, and Petty F. Plasma levels of gamma-aminobutyric acid and panic disorder. Psychiatry Res 1996;63:223-225.
114. 114. Breslow MF, Frankhauser MP, Patter RY, Meredith KE, Misiaszek J, Hope DG Jr. Role of γ-aminobutyric acid in antipanic drug efficacy. Am J Psychiatry 1989;146:353-359.
115. 115. Rattray M, Singhvi S, Wu PY, Andrews N, File SE. Benzodiazepines increase preprocholecystokinin messenger RNA levels in rat brain. Eur J Pharmacol 1993;245:193-196.
116. 116. Harro J, Kiivet RA, Lang A, Vasar E. Rats with anxious or non-anxious type of exploratory behavior differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res 1990;39:63-71.
117. 117. Nutt DJ, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 1990;47:917-925.
118. 118. Baker GB, Wong JTF, Yeung JM, Coutts RT. Effects of the antidepressant phenelzine on brain levels of γ-aminobutyric acid (GABA). J Affec Disord 1991;21:207-211.
119. 119. Paslawski T, Treit D, Baker GB, George M, Coutts RT. The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases brain GABA. Psychopharmacology 1996;127:19-24.
120. A receptor subunit mRNA levels. Neuropharmacology 1996;35:1475-1482.
121. 121. Keck PE, Taylor VE, Turrul KC, McElroy SL, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993;33:542-546.
122. 122. Shekhar A, Keim SR, Simon JR, McBride WJ. Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Pharmacol Biochem Behav 1996;55:249-256.
123. 123. Marazziti D, Rotondo A, Martini C, Giannaccini G, Lucacchini A, Pancioliguadagnucci ML, Diamond BI, Borison R, Cassano GB. Changes in peripheral benzodiazepine receptors in patients with panic disorder and obsessive-compulsive disorder. Neuropsychobiology 1994;29:8-11.
124. 124. Rocca P, Ferrero P, Gualerzi A, Zanalda E, Maina G, Bergamasco B, Ravizza L. Peripheral-type benzodiazepine receptors in anxiety disorders. Acta Psychiatrica Scand 1991;84:537-544.
125. 125. Boutihillier A, De Montigny C. Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystonin: an electrophysiological study in the rat. Eur J Pharmacol 1988;5:135.
126. 126. Csonka E, Fekete M, Nagy G, Szanto-Fekete M, Feledgy G, Penke B, Kovaks K. Anxiogenic effect of cholecystokinin in rats. In: Penke B, Torok A, eds. Peptides. New York: de Gruyter 1988: 249-252.
127. 127. De Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 1989;46:511-516.
128. 128. Harro J, Pold M, Vasar E. Anxiogenic-like action of caerulin, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. Naunyn-Schmiederberg's Arch Pharmacol 1990;341:62-67.
129. 129. Harro J, Vasar E. Bradwejn J. CCK in animal and human research on anxiety. Trends Pharmacol Sci 1993;14:244-249.
130. 130. Chopin P, Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology 1993;110:409-414.
131. 131. Crawley JN. Interactions between cholecystokinin and other neurotransmitter systems. In: Bradwejn J, Vasar E, eds. Cholecystokinin and anxiety: from neuron to behavior. New York: Springer 1995:181.
132. 132. Yakish TL, Furui T, Kanaeati IS, Go VLW. Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems. Brain Res 1987;406:207-212.
133. 133. Gemignani A, Paudice P, Bonanno G, Raiteri M. Pharmacological discrimination between γ-ammobutyric acid type B receptors regulating cholecystokinin and somatostatin release from rat neocortex synaptosomes. Mol Pharmacol 1994;46:558-562.
134. 3H]γ-aminobutyric acid release in slices from various brain areas. Eur J Pharmacol 1993;250:423-430.
135. 135. Rakovska A. Cholecystokinin-GABA interactions in rat striatum. Neuropeptides 1995;29:257-262.
136. 136. Harro J, Vasar E. Long-term benzodiazepine treatment produces changes in cholecystokinin receptor binding in rat brain. Eur J Pharmacol 1993;180:77-83.
137. 137. Tao R, Ma ZY, Auerbach SB. Differential regulation of 5-hydroxytryptamine release by GABA (A) and GABA (B) receptors in midbrain raphe nuclei and forebrain of rats. Br J Pharmacol 1997;119:1375-1384.
138. 138. Rasmussen K. CCK, schizophrenia and anxiety - CCK-B antagonists inhibit the activity of brain dopamine neurons. Ann Acad Sci 1994;713:300-311.
139. 139. Vaccarino FJ. Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors. Neurosci Biobehav Rev 1994;18:207-214.
140. 140. Hokfelt T, Skirboll L, Rehfeld JF, Goldstein M, Markey K, Dann O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 1994;5:2093-2124.
141. 141. Kosaka T, Kosaka K, Tateishi K, Hamaoka Y, Yanaihara N, Wu JY, Hama K. GABAergic neurons containing CCK-8-Like and/or VIP-like immunoreactivity in the rat hippocampus and dentate gyrus, J Compreh Neurol 1985:239:420-430.
142. 142. Crawley JN. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. J Neurosci 1992;12: 3380-3391.
143. 143. Abelson, JL. Cholecystokinin in psychiatric research: a time for cautious excitement. J Psychiatric Res 1995;5:389-396.
144. 144. Vasar E. Cholecystokinin in animal model of anxiety. Proc of the 19th annual meeting of the Canadian College of Neuropsychopharmacology, Toronto, ON, Canada, 1996.
145. 145. Boulenger JP, Jerabek J, Jolicoeur FB, Lavalée YJ, Leduc R, Cadieux A. Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am J Psychiatry 1996;153:114-116.
146. 146. Stein MB, Huager RL, Dhalla KS, Chartier MJ, Asmundson GJG. Plasma neuropetide Y in anxiety disorders: findings in panic disorder and social phobia. Psychiatry Res 1996;59:183-188.
147. 147. Yeragani VK, Spinivasan K, Pohl R, Berger R, Balon R, Berchou R. Sodium lactate increases sympathovagal ratios in normal control subjects: spectral analysis of heart rate, blood pressure, and respiration. Psychiatry Res 1994;54:97-114.
148. 148. Morino P, Herrera-Marschite M, Catel MN, Ungerstedt U, Varro A, Dockray G, Hökfelt T. Cholecystokinin in cortico-striatal neurons in the rat: immunohistochemical studies at the light and electron micropical level. Eur J Neurosci 1994;6:681-692.
149. 149. Migaud M, Roques BP, Durieux C. Effects of cholecystokinin octapeptide and BC 264, a potent and selective CCK-B agonist on aspartate and glutamate release from rat hippocampal slices. Neuropharmacology 1994;33:737-743.
150. 150. Herrera-Marschitz M, Meana JJ, Höselt T, You ZB, Morino P, Brosin E, Ungerstedt U. Cholecystokinin is released from a crossed corticostriatal pathway. NeuroReport 1992;3:905-908.
151. 151. Blacker D, Broberger C, Ogren SO, Hokfelt T. Cholecystokinin B receptor antagonists enhance the locomotor response to the N-methyl-D-aspartate antagonists phencyclidine and dizocilpine maleate. Neuroscience 1997;76:1057-1067.
152. 152. Akiyoshi J, Moriyama T, Isogawa K, Miyamoto M, Sasaki I, Kuga K, Yamamoto N, Yamada K, Fujii I. CCK-4-induced calcium mobilization in T cells is enhanced in panic disorder. J Neurochem 1996;66:1610-1616.
153. 153. Zacharko RM, Koszycki D, Mendella PD, Bradwejn J. Behavioral, neurochemical, anatomical and electrophysiological correlates of panic disorder: multiple transmitter interactions and neuropeptide colocalization. Prog Neurobiol 1995;47:371-423.